Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Company Overview

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $1.91 to $2.01
• 50-Day Range: $1.66 to $2.26
• 52-Week Range: $1.12 to $4.20
• Volume: 185,188 shs
• Average Volume: 237,995 shs
• Market Capitalization: $145.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Moderate Buy

Inhibikase Therapeutics Stock Analysis - MarketRank™

Inhibikase Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 845th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Inhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibikase Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibikase Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibikase Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.95% of the outstanding shares of Inhibikase Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Inhibikase Therapeutics has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in Inhibikase Therapeutics has recently increased by 2.11%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibikase Therapeutics does not currently pay a dividend.

Dividend Growth

Inhibikase Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.95% of the outstanding shares of Inhibikase Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Inhibikase Therapeutics has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in Inhibikase Therapeutics has recently increased by 2.11%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of Inhibikase Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.81% of the stock of Inhibikase Therapeutics is held by institutions.

IKT Stock Analysis - Frequently Asked Questions

How have IKT shares performed this year?

Inhibikase Therapeutics' stock was trading at $3.25 at the beginning of the year. Since then, IKT shares have decreased by 39.7% and is now trading at $1.96.
View the best growth stocks for 2025 here.

How were Inhibikase Therapeutics' earnings last quarter?

Inhibikase Therapeutics, Inc. (NYSE:IKT) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.24. The business earned $0.33 million during the quarter.

When did Inhibikase Therapeutics' stock split?

Inhibikase Therapeutics's stock reverse split on the morning of Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Inhibikase Therapeutics IPO?

Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) served as the underwriter for the IPO.

Who are Inhibikase Therapeutics' major shareholders?

Inhibikase Therapeutics' top institutional investors include ADAR1 Capital Management LLC (6.89%), Stonepine Capital Management LLC (1.23%), Goldman Sachs Group Inc. (0.22%) and Blair William & Co. IL (0.21%). Insiders that own company stock include Milton H Werner and Arvind Kush.
View institutional ownership trends.

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inhibikase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 6/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:IKT
• CIK: 1750149
• Web: www.inhibikase.com
• Phone: 678-392-3419
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.50
• High Stock Price Target: $8.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +231.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.03 million
• Net Margins: N/A
• Pretax Margin: -22,978.75%
• Return on Equity: -350.63%
• Return on Assets: -201.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $260 thousand
• Price / Sales: 560.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 1.10

Miscellaneous

• Outstanding Shares: 74,342,000
• Free Float: 66,178,000
• Market Cap: $145.71 million
• Optionable: Not Optionable
• Beta: 0.94